齐拉西酮联合丙戊酸钠治疗精神分裂症的临床疗效分析

柏彩云

广西脑科医院2病区精神科，广西柳州545005

[摘要]目的探讨齐拉西酮联合丙戊酸钠治疗精神分裂症的临床疗效。方法通过对整群选取2011年2月—2015年4月在该院进行治疗的82例精神分裂症患者随机分组，其中对照组患者应用齐拉西酮治疗，实验组患者实施齐拉西酮联合丙戊酸钠治疗。观察比较两组患者治疗效果、PASS评分和不良反应发生率差异。结果实验组患者总有效率明显高于对照组、PASS评分显著改善，差异具有统计学意义（P<0.05），两组患者不良反应发生率差异无统计学意义（P>0.05）。结论齐拉西酮联合丙戊酸钠治疗精神分裂症可明显提高治疗效果，降低PASS评分，无严重不良反应，其具有安全有效等特点，临床值得推广应用。

[关键词]齐拉西酮；丙戊酸钠；精神分裂症

[中图分类号]R74

[文献标识码]A

[文章编号]1674-0742（2015）10（a）－0145-02

[作者简介]柏彩云(1970.7－)，女,湖南祁阳人,大专，中级，研究方向:临床精神病。

Abstract[]Objective To evaluate the clinical efficacy of ziprasidone in the treatment of schizophrenia combined with valproate.Methods By February 2011 to April 2015 in our hospital for treatment of 82 cases of patients with schizophrenia randomized con鄄trol group in which patients ziprasidone treatment, the experimental group was treated ziprasidone joint valproate sodium treatment.To compare the two groups of patient outcomes, PASS scores and differences in the incidence of adverse reactions.Results The experimental group was significantly higher total efficiency, PASS scores improved significantly, the difference was statistically sig鄄nificant (P<0.05), the incidence of adverse reactions was not statistically significant (P>0.05).Conclusion Ziprasidone joint val鄄proate therapy can significantly improve the treatment of schizophrenia, reduce PASS scores, no serious adverse reactions, it is safe and effective features, clinical worth promoting.

收稿日期：（2015-07-11）

Clinical Efficacy of Ziprasidone Combined with Sodium Valproate Treat鄄ment of Schizophrenia

BAI Cai-yun

Psychiatry Department, The Second Brain Hospital of Guangxi Liuzhou, Liuzhou, Guangxi, 545005 China

[Key words]Ziprasidone; Sodium valproate; Schizophrenia

精神分裂症发病机制尚未完全明确，多发生于青壮年，临床表现为精神活动及环境不协调，其具有发病慢、病程长、致残率高等特点，若治疗不及时可能导致难治性精神分裂症，其具有治愈率低、预后差等特点，影响治疗效果和患者的社会功能，增加经济负担。文献报道[1]，精神分裂症患病率为1.5%~4.7%。齐拉西酮为新型抗精神病药，化学结构多样，作用靶位专一，研究显示[2]，齐拉西酮治疗阴性症状效果更佳显著。丙戊酸钠治疗精神分裂症具有一定效果，但齐拉西酮联合丙戊酸钠治疗精神分裂症的报道较少。……